Tetrahydrocannabinol - Pharmacokinetics
Research News and Information

Tuesday, November 24, 2009

Comparison of subjective, pharmacokinetic, and physiological effects of marijuana smoked as joints and blunts.

12 May 2009 Recent increases in marijuana smoking among the young adult population have been accompanied by the popularization of smoking marijuana as blunts instead of as joints. Blunts consist of marijuana wrapped in tobacco leaves, whereas joints consist of ... Read more...

Cannabis coadministration potentiates the effects of "ecstasy" on heart rate and temperature in humans.

11 May 2009 This study assessed the acute physiologic effects over time of (co)administration of Delta9-tetrahydrocannabinol (Delta9-THC) (the main psychoactive compound of cannabis) and 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") in 16 healthy ... Read more...

Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis.

30 Mar 2009 CONTEXT: Cannabis sativa use can impair verbal learning, provoke acute psychosis, and increase the risk of schizophrenia. It is unclear where C. sativa acts in the human brain to modulate verbal learning and to induce psychotic symptoms. OBJECTIVES: ... Read more...

Latest indexed articles for 'Tetrahydrocannabinol - Pharmacokinetics'

These are the very latest articles for this heading:

• Comparison of subjective, pharmacokinetic, and physiological effects of marijuana smoked as joints and blunts. 12 May 2009
• Cannabis coadministration potentiates the effects of "ecstasy" on heart rate and temperature in humans. 11 May 2009
• Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. 30 Mar 2009
• Effect of abdominal surgery on the intestinal absorption of lipophilic drugs: possible role of the lymphatic transport. 29 Mar 2009
• Emerging strategies for exploiting cannabinoid receptor agonists as medicines. 30 Jan 2009
• Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. 30 Dec 2008
• Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. 10 Nov 2008
• Pro-drugs for indirect cannabinoids as therapeutic agents. 29 Sep 2008
• [Delta-9-tetrahydrocannabinol pharmacokinetics] 27 Aug 2008
• Preformulation studies of a prodrug of Delta9-tetrahydrocannabinol. 26 Aug 2008
• Delta-9-tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg THC. 8 Aug 2008
• Chemical stability and bioadhesive properties of an ester prodrug of Delta 9-tetrahydrocannabinol in poly(ethylene oxide) matrices: effect of formulation additives. 3 Jul 2008
• Behavioral sensitization to delta 9-tetrahydrocannabinol and cross-sensitization with morphine: differential changes in accumbal shell and core dopamine transmission. 26 Jun 2008
• [What sense in cannabinoid use as regulated by Italian DM 18/04/07? Pharmacological and legal considerations] 30 May 2008
• Effect of intrapulmonary tetrahydrocannabinol administration in humans. 28 May 2008
• Disposition of Delta tetrahydrocannabinol in CF1 mice deficient in mdr1a P-glycoprotein. 5 Mar 2008
• A role for p53 in the regulation of lysosomal permeability by delta 9-tetrahydrocannabinol in rat cortical neurones: implications for neurodegeneration. 2 Feb 2008
• Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain. 30 Dec 2007
• [Fitness to drive in spite (because) of THC] 29 Jun 2007
• Pharmacokinetic properties of delta9-tetrahydrocannabinol in serum and oral fluid. 30 May 2007

See a longer list of these articles.

Technical information about 'Tetrahydrocannabinol'

Definition: A psychoactive compound extracted from the resin of Cannabis sativa (marihuana, hashish). The isomer delta-9-tetrahydrocannabinol (THC) is considered the most active form, producing characteristic mood and perceptual changes associated with this compound. Dronabinol is a synthetic form of delta-9-THC.

Chemical name: 6H-Dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6aR-trans)-

Registry Number: 1972-08-3

Descriptor UI: D013759

Alternative terms: Tetrahydrocannabinol; delta(1)-Tetrahydrocannabinol; THC; delta(9)-Tetrahydrocannabinol; delta(9)-THC; Dronabinol; 9-ene-Tetrahydrocannabinol; 9 ene Tetrahydrocannabinol; delta(1)-THC; Tetrahydrocannabinol, (6a-trans)-Isomer; Tetrahydrocannabinol, Trans-Isomer; Tetrahydrocannabinol, Trans Isomer; Tetrahydrocannabinol, (6aS-cis)-Isomer; Tetrahydrocannabinol, Trans-(+-)-Isomer; Marinol; Solvay Brand of Tetrahydrocannabinol; Tetrahydrocannabinol, (6aR-cis)-Isomer;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists; biosynthesis;

Pharmacological Action: Hallucinogens; Psychotropic Drugs; Analgesics, Non-Narcotic;

Tree Number: D02.455.849.090.810;

History Note: 77(71); was see under CANNABIS 1975-76